Trial to evaluate combination of CAR-T and pembrolizumab for metastatic colorectal cancer

Although colorectal cancer mortality has declined steadily since the 1940s, the long-term prognosis for patients with late-stage metastatic disease has remained relatively poor.The 5-year survival rate for patients with metastatic colorectal cancer stands at 14%, according to American Cancer Society data.Researchers hope to address the unmet treatment needs of these patients by combining chimeric antigen receptor T-cell therapy with an immune checkpoint inhibitor.Celyad Oncology has collaborated with Merck to conduct the KEYNOTE-B79 clinical trial, a phase 1b study to evaluate CYAD-101 —Read More

Share on facebook
Share on twitter
Share on linkedin